home
about us
member log-in
contact us

PRODUCTS
MUNICIPAL BONDS
INDEX FUNDS
- Total Asset Fund (TAF)
EVENTS
MARKET RESEARCH

Recent Quotes

View Full List

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

BeiGene, Ltd. - American Depositary Shares (NQ:BGNE)

184.71 UNCHANGED

Last Price Updated: 4:00 PM EST, Dec 31, 2024 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about BeiGene, Ltd. - American Depositary Shares

< Previous 1 2 3 4 5 6 7 8 9

...

16 17 Next >

HBM Gets Health Boost From Drug Licensing Deals ↗

December 22, 2023

Key Takeaways: Nona Biosciences, a subsidiary of HBM Holdings, has struck a licensing-out deal with a Pfizer-owned biotech for an initial sum of $53 million and milestone payments of up to $1.05...

Via Benzinga

FDA Approves Label Update for BRUKINSA® (zanubrutinib) in Chronic Lymphocytic Leukemia (CLL)

December 22, 2023

From BeiGene, Ltd.

Via Business Wire

BeiGene to Present at the 42nd Annual J.P. Morgan Healthcare Conference

December 21, 2023

From BeiGene, Ltd.

Via Business Wire

Citigroup Maintains Buy Rating for BeiGene: Here's What You Need To Know ↗

September 21, 2023

Via Benzinga

BeiGene to Host ASH Investor Meeting in Person and via Webcast on December 10, 2023

November 29, 2023

From BeiGene, Ltd.

Via Business Wire

BeiGene to Present New Data Highlighting Hematology Portfolio and Pipeline Strengths at ASH 2023

November 28, 2023

From BeiGene, Ltd.

Via Business Wire

Week In Review: BeiGene Signs $1.3 Billion Deal For Preclinical CDK2 Inhibitor From Boston’s Ensem ↗

November 25, 2023

Beijing’s BeiGene acquired global rights to a preclinical novel cyclin-dependent kinase 2 (CDK2) inhibitor from Boston’s Ensem Therapeutics in a $1.3 billion agreement. Ensem will receive an upfront...

Via Talk Markets

BeiGene and Ensem Therapeutics Announce Partnership to Advance Differentiated CDK2 Inhibitor

November 21, 2023

From BeiGene, Ltd.

Via Business Wire

BeiGene Receives European Commission Approval for BRUKINSA® (zanubrutinib) for the Treatment of Relapsed or Refractory Follicular Lymphoma

November 17, 2023

From BeiGene, Ltd.

Via Business Wire

7 Biotech Stocks to Buy for Big-Time Gains ↗

November 10, 2023

Biotech stocks can be big winners because they're at the forefront of scientific innovation and push the boundaries of medical research.

Via InvestorPlace

BeiGene Continues Global Growth with Third Quarter 2023 Financial Results and Business Updates

November 09, 2023

From BeiGene, Ltd.

Via Business Wire

BeiGene to Present at the Jefferies London Healthcare Conference

November 08, 2023

From BeiGene, Ltd.

Via Business Wire

Ryanair Holdings, Prime Medicine And Other Big Stocks Moving Higher In Monday's Pre-Market Session ↗

November 06, 2023

U.S. stock futures traded higher this morning on Monday. Here are some big stocks recording gains in today’s pre-market trading session.

Via Benzinga

Why Bluegreen Vacations Shares Are Trading Higher By Around 105%? Here Are Other Stocks Moving In Monday's Mid-Day Session ↗

November 06, 2023

Gainers Carbon Revolution Public Limited (NASDAQ: CREV) shares jumped 396.2% to $145.49 after gaining 100% on Friday. The company’s stock began trading on Friday following merger with Twin Ridge...

Via Benzinga

Western Digital, JinkoSolar, Lumentum Holdings And Other Big Stocks Moving Higher On Monday ↗

October 30, 2023

U.S. stocks traded higher, with the Nasdaq Composite gaining more than 100 points on Monday. Here are some big stocks recording gains in today’s session.

Via Benzinga

Topics Stocks

Why ON Semiconductor Shares Are Trading Lower By Around 18%? Here Are Other Stocks Moving In Monday's Mid-Day Session ↗

October 30, 2023

Gainers Miromatrix Medical Inc. (NASDAQ: MIRO) shares climbed 230.7% to $3.3401 after United Therapeutics agreed to acquire the company for $3.25 per share in cash.

Via Benzinga

Why Biophytis Shares Are Trading Higher By Over 12%: Here Are 20 Stocks Moving Premarket ↗

October 30, 2023

Gainers

Via Benzinga

Week In Review: China's Biopharmas Announce $2.5 Billion In Deals ↗

October 21, 2023

KBP Biosciences sold global rights for its hypertension candidate to Novo Nordisk in an agreement worth up to $1.3 billion. Also, EpimAb Bio sold the rights to use its Fabs-In-Tandem Immunoglobulin...

Via Talk Markets

BRUKINSA® Receives Positive Recommendation from NICE in U.K. for Adult Patients with Chronic Lymphocytic Leukemia

October 20, 2023

From BeiGene, Ltd.

Via Business Wire

BeiGene's Poster For Upcoming Conference Reveals Promising Lung Cancer Data ↗

October 18, 2023

BeiGene Ltd's (NASDAQ: BGNE) Phase 3 RATIONALE 315 study met its dual primary endpoints of major pathological response (MPR) by Blinded Independent Pathology Review (BIPR)

Via Benzinga

BeiGene Announces the Phase 3 RATIONALE 315 Trial Met Primary Endpoints of Major Pathological Response Rate and Event-Free Survival for Tislelizumab Plus Chemotherapy in Patients with Resectable Non-Small Cell Lung Cancer (NSCLC)

October 17, 2023

From BeiGene, Ltd.

Via Business Wire

BeiGene Announces Late-Breaking Data at ESMO Showing Tislelizumab plus Chemotherapy Significantly Improved Overall Survival at Final Analysis in First-Line Advanced Gastric or Gastroesophageal Junction Adenocarcinoma

October 17, 2023

From BeiGene, Ltd.

Via Business Wire

BeiGene Receives Positive CHMP Opinion for BRUKINSA® (zanubrutinib) in Relapsed or Refractory Follicular Lymphoma

October 13, 2023

From BeiGene

Via Business Wire

10 Health Care Stocks Whale Activity In Today's Session ↗

October 02, 2023

Via Benzinga

Week In Review: Everest Acquires Novel Autoimmune Therapy In $132 Million Agreement ↗

September 23, 2023

Shanghai Everest Medicines acquired China/Asian rights to a novel therapy for autoimmune diseases from Kezar Life Sciences of South San Francisco in a deal worth $132.5 million. The company will make...

Via Talk Markets

Why Gorilla Technology Group Shares Are Trading Lower By 25%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session ↗

September 20, 2023

Gainers MSP Recovery, Inc. (NASDAQ: LIFW) shares jumped 104.5% to $0.1916.

Via Benzinga

Amazon Poaches Microsoft's Product Chief, Google And DoD Team Up For AI-Powered Microscope To Identify Cancer, Rocket Lab's 41st Mission Succumbed To Technical Issues: Today's Top Stories ↗

September 19, 2023

Bloomberg

Via Benzinga

Chinese Drugmaker BeiGene And Novartis Move Out From Second Cancer Drug Pact ↗

September 19, 2023

BeiGene Ltd (NASDAQ: BGNE) said it would regain rights to develop, manufacture, and commercialize Tevimbra (tislelizumab), its cancer drug, from Novartis AG (NYSE: NVS).

Via Benzinga

BeiGene Announces Positive Regulatory Updates in Europe and the U.S. After Recently Regaining Global Rights for TEVIMBRA®

September 19, 2023

From BeiGene, Ltd.

Via Business Wire

BeiGene Strengthens Global Portfolio and Regains Full Rights from Novartis for Anti-PD-1 Antibody TEVIMBRA® (tislelizumab)

September 19, 2023

From BeiGene, Ltd.

Via Business Wire

< Previous 1 2 3 4 5 6 7 8 9

...

16 17 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Home
About Us
Products
Municipal Bonds
Index Funds
Seminars & Events
Market Research
Contact Us
Member Section
Privacy Policy
Terms & Conditions
Security Notice
Customer Service

Securities offered through Purshe Kaplan Sterling Investments, member FINRA / SIPC, Headquartered at 80 State Street,
Albany, NY 12207
Purshe Kaplan Sterling Investments and Tamar Securities, LLC are not affiliated companies.
Tamar Securities, LLC is a Registered Investment Adviser. Advisory services are only offered to clients or prospective clients where Tamar Securities, LLC
and its representatives are properly licensed or exempt from licensure. Past performance is no guarantee of future returns. Investing involves risk and possible loss of principal capital.
No advice may be rendered by Tamar Securities, LLC unless a client service agreement is in place.

NOT FDIC INSURED. NOT BANK GUARANTEED. MAY LOSE VALUE, INCLUDING LOSS OF PRINCIPAL. NOT INSURED BY ANY STATE OR FEDERAL AGENCY.
Web development by IBCnet.com